China’s first self-developed COVID-19 mRNA vaccine officially approved for marketing
China’s first self-developed COVID-19 mRNA vaccine officially approved for marketing
News
-
CPIVC NEWS
CanSinoBIO initiates Phase I/II trial for 24-valent pneumococcal polysaccharide conjugate vaccine
CanSinoBIO initiates Phase I/II trial for 24-valent pneumococcal polysaccharide conjugate vaccine
learn more »
CPIVC 2026-09-12
-
CPIVC NEWS
China's NMPA approves Sinovac's serum-free rabies vaccine
China's NMPA approves Sinovac's serum-free rabies vaccine
learn more »
CPIVC 2026-09-12
-
CPIVC NEWS
FDA clears CSPC to conduct U.S. clinical trials of mpox mRNA vaccine SYS6037
FDA clears CSPC to conduct U.S. clinical trials of mpox mRNA vaccine SYS6037
learn more »
CPIVC 2026-09-12
-
CPIVC NEWS
Luye Pharma advances therapeutic mRNA vaccine LY01620 into Phase II for HPV lesions
Luye Pharma advances therapeutic mRNA vaccine LY01620 into Phase II for HPV lesions
learn more »
CPIVC 2026-09-12
-
CPIVC NEWS
FDA allows CSPC Pharmaceutical to conduct clinical trials of recombinant RSV vaccine SYS6057 in U.S.
FDA allows CSPC Pharmaceutical to conduct clinical trials of recombinant RSV vaccine SYS6057 in U.S.
learn more »
CPIVC 2026-09-12
-
CPIVC NEWS
China's CanSino accelerates overseas growth as vaccine portfolio expands
China's CanSino accelerates overseas growth as vaccine portfolio expands
learn more »
CPIVC 2026-09-12
Scan the QR code to follow
us on WeChat
京公网安备 11010802041931号 © 2024 cpivc.com